MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 33.33 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $7.271 million which beat the analyst consensus estimate of $6.475 million by 12.29 percent. This is a 14.53 percent decrease over sales of $8.507 million the same period last year.